Given that TGF-β signaling and ECM remodeling are crucial in fibrosis-associated glioblastoma recurrence, strategies targeting fibrosis-related pathways have shown potential in enhancing the efficacy of anti-CSF-1R therapy and in reducing glioblastoma recurrence in preclinical models [101]. The gene discussed is CSF1R; the disease is glioblastoma.